

## STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

ATTORNEYS AT LAW

1100 NEW YORK AVENUE, N.W. . WASHINGTON, D.C. 20005-3934

PHONE (202) 371-2600 • FACSIMILE (202) 371-2540 • www.skgf.com



ROBERT GREENE STERNE EDWARD J KESSLER JORGE A. GOLDSTEIN SAMUEL L FOX\*\*\*
DAVID K.S. CORNWELL ROBERT W ESMOND TRACY-GENE G DURKIN MICHELE A CIMBALA MICHAEL B RAY ROBERT E SOKOHL ERIC K. STEFFE MICHAEL O LEE STEVEN R LUDWIG

JOHN M COVERT
LINDA E ALCORN
ROBERT C MILLONIG
MICHAEL V MESSINGER
JUDITH U KIM
TIMOTHY J SHEA, JR
DONALD R MCPHAIL
PATRICK E GARRETT
JEFFREY T HELVEY\*
HEIDI L KRAUS
JEFFREY R KURIN
RAYMOND MILLIEN
PATRICK D O'BRIEN

LAWRENCE B BUGAISKY
CRYSTAL D SAYLES
EDWARD W YEE
ALBERT L FERRO\*
DONALD R BANOWIT
PETER A JACKMAN
MOLLY A MCCALL
TERESA U MEDLER
JEFFREY S WEAVER
KRISTIN K VIDOVICH
KENDRICK P PATTERSON
DONALD J FEATHERSTONE
GRANT E REED

VINCENT L CAPUANO
JOHN A HARROUN\*
ALBERT J FASULO II\*
ELDORA ELLISON FLOYD\*
W RUSSELL SWINDELL
THOMAS C FIALA
BRIAN J DEL BUONO\*
VIRGIL L BEASTON\*
RYAN J STAMPER\*
KAREN R MARKOWICZ\*\*
SUZANNE E ZISKA\*\*
ANDREA J KAMAGE\*\*
NANCY J LEITH\*\*

ELIZABETH J HAANES\*\*
MARK P TERRY\*\*
JOSEPH M CONRAD, III\*\*
DOUGLAS M WILSON\*\*
REGINALD D LUCAS\*\*
ANN E SUMMERFIELD\*\*
CYNTHIA M BOUCHEZ\*\*
HELENE C CARLSON\*\*
BRUCE E CHALKER\*\*
DUSTIN T JOHNSON\*\*
MATTHEW J DOWD\*\*

\*LIMITED TO MATTERS
AND PROCEEDINGS BEFORE
FEDERAL COURTS & AGENCIES
\*\*REGISTERED PATENT AGENT
\*\*\*SENIOR COUNSEL

WRITER'S DIRECT NUMBER: (202) 371-2560
INTERNET ADDRESS:
RESMOND@SKGF.COM

August 2, 2001

Commissioner for Patents Washington, D.C. 20231

**Box Patent Application** 

Re: U.S. Non-Provisional Patent Application under 37 C.F.R. § 1.53(b)

Appl. No. To be assigned; Filed: August 2, 2001 (Herewith)
For: Method of Identifying Immunosuppressive Agents

Inventors: Kasibhatla et al.

Our Ref: 1735.0470001/RWE/ALS

Sir:

The following documents are forwarded herewith for appropriate action by the U.S. Patent and Trademark Office:

- 1. USPTO Utility Patent Application Transmittal Form (PTO/SB/05)(in duplicate);
- 2. U.S. Utility Patent Application entitled:

Method of Identifying Immunosuppressive Agents

and naming as inventors:

Shailaja Kasibhatla Douglas R. Green Ben Tseng Commissioner for Patents August 2, 2001 Page 2

the application consisting of:

- a. A specification containing:
  - i. 34 pages of description prior to the claims;
  - ii. 9 pages of claims (35 claims);
  - iii. 1 page abstract;
- b. 5 sheets of drawings: (Figures 1-2; 3, 4, 5, and 6);
- c. 1 page of a paper copy of the sequence listing;
- d. A computer readable copy of the sequence listing. In accordance with 37 C.F.R. § 1.821(f), the paper copy of the sequence listing and the computer readable copy of the sequence listing submitted herewith in the above application are the same;
- e. an Application Data Sheet (37 C.F.R. § 1.76);
- 3. Authorization to Treat a Reply As Incorporating An Extension of Time Under 37 C.F.R. § 1.136(a)(3)(in duplicate); and
- 4. Two (2) return postcards.

The name of the assignee is Cytovia, Inc.

Send correspondence to Customer Number 26111.

It is respectfully requested that, of the two attached postcards, one be stamped with the filing date of these documents and returned to our courier, and the other, prepaid postcard, be stamped with the filing date and unofficial application number and returned as soon as possible.

This patent application is being submitted under 37 C.F.R. § 1.53(b) without Declaration and without filing fee.

Respectfully submitted,

Szerne, Kessler, Goldøvein & Fox p.l.l.c.

Robert W. Esmond Attorney for Applicants Registration No. 32,893

PTO/SB/05 (03-01)

Approved for use through 10/31/2002. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCIA.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR § 1 53(b))

Attorney Docket No.		1735.0470001/RWE/ALS				
First Invent	or	Shailaja Kasibhatla				
Title	Method of Identi	fying Immunosuppressive Agents	0.4.0			
Express Ma	il Label No.		÷1			

	APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application contents			AL	ASSISTANT Commissioner for Patients  ADDRESS TO:  Box Patent Application Washington, DC 20231						
			(Submit an original, and a duplicate for fee processing)		<ol> <li>CD-ROM or CD-R in duplicate, large table or Computer Program         (Appendix)</li> <li>Nucleotide and/or Amino Acid Sequence Submission         (if applicable, all necessary)</li> <li>Computer Readable Form (CRF)</li> </ol>						
1	3.	⊠	Specification [Total Pages 44]	b. Specification Sequence Listing on:							
Ĭ	٠.		(preferred arrangement set forth below)  - Descriptive title of the Invention  - Cross Reference to Related Applications  - Statement Regarding Fed sponsored R & D  - Reference to sequence listing, a table, or a computer program listing appendix  - Background of the Invention		i. CD-ROM or CD-R (2 copies); or						
l					ii. 🔀 paper						
					c. Statements verifying identity of above copies						
			Background of the Invention     Brief Summary of the Invention     Brief Description of the Drawings (tf filed)	ACCOMPANYING APPLICATION PARTS							
energ.			- Detailed Description - Claim(s)			Assignment l	Papers (cover shee	t & document(s))			
	4. 🗵	M	- Abstract of the Disclosure  Drawings (35 U.S.C. 113) [Total Sheets 5]	10.		37 CFR 3.73 (when there is	(b) Statement an assignee)	Power of Attorney			
		5. Oath or Declaration [Total Pages]		11.		English Tran	slation Document	(if applicable)			
Heart for four factors from the factors			a. Newly executed (original or copy)	12.		Information I Statement (II	Disclosure DS)/PTO-1449	Copies of IDS Citations			
		b. Copy from a prior application (37 CFR 1.63(d))  (for continuation/divisional with Box 18 completed)		13.		Preliminary A	Amendment				
3	i. DELETION OF INVENTOR(S)  Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR §§ 1.63(d)(2) and 1.33(b).		14. Return Receipt Postcard (MPEP 503) (Should be specifically itemized)								
			named in the prior application, see 37 CFR §§ 1.63(d)(2) and 1.33(b).	15.		Certified Cop	py of Priority Doci	ument(s)			
	6. Application Data Sheet. See 37 CFR 1.76.			16.	16. Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.						
				17.	17. Other: Authorization under 37 C.F.R. § 1.136(a)(3)						
Ŧ				Other: The name of the assignee is: Cytovia, Inc.							
	18	8. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, r in an Application Data Sheet under 37 CFR 1.76									
	υ.	··									
			Continuation Divisional Continuation-in-Part (Corior application information: Examiner	n No:/ Unit:							
	Fo	r (CO)	NTINUATION OR DIVISIONAL APPS only: The entire disclosure of t	he pri	or appl	ication, from w	vhich an oath or de	claration is supplied under Box 5b, is			
	ഹ	nside	red a part of the disclosure of the accompanying continuation or division the properties of the disclosure of the accompanying continuation or division that the submitted from the subm	ivisional application and is hereby incorporated by reference. The incorporation can only							
			19. CORRESPONDENCE ADDRESS								
	Customer Number or Bar Code Label				or Correspondence address below						
			Customer No. 26111 (Insert Customer No. of Att	$1_{hh}$	rh har code label here)						
NAME STERNE, KESSLER, GOLDSTEIN & FOX P.L. L. C.											
	_	Attorneys at Law									
	_	ADDRESS         1100 New York Avenue, N.W.           CITY         Washington         STATE			DC ZIP CODE 20005						
		OUN		+		1-2600	FAX	(202) 371-2540			
	_		(Print/Type) Robert W. Esmond		Registration No. (Attorney/Agent) 32,893						
	S	IGNA	TURE John Somons					Date August 2, 2001			

Burden Hour Statement: this form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231. SKGF Rev 3/29/01 mac